Alpine Associates Management Inc. trimmed its position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 32.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 860,717 shares of the health services provider's stock after selling 420,180 shares during the period. Amedisys accounts for approximately 3.8% of Alpine Associates Management Inc.'s holdings, making the stock its 10th biggest position. Alpine Associates Management Inc. owned approximately 2.63% of Amedisys worth $83,068,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. KBC Group NV acquired a new stake in Amedisys in the 3rd quarter valued at approximately $63,000. Innealta Capital LLC acquired a new stake in shares of Amedisys during the second quarter worth approximately $64,000. Covestor Ltd grew its stake in Amedisys by 134.2% in the 1st quarter. Covestor Ltd now owns 780 shares of the health services provider's stock valued at $72,000 after buying an additional 447 shares during the last quarter. Signaturefd LLC lifted its position in Amedisys by 88.2% during the 2nd quarter. Signaturefd LLC now owns 1,131 shares of the health services provider's stock worth $104,000 after acquiring an additional 530 shares during the last quarter. Finally, CWM LLC boosted its holdings in Amedisys by 14.5% during the third quarter. CWM LLC now owns 2,190 shares of the health services provider's stock valued at $211,000 after acquiring an additional 277 shares during the period. Institutional investors own 94.36% of the company's stock.
Amedisys Trading Down 0.1 %
Shares of AMED traded down $0.06 during trading hours on Wednesday, hitting $89.94. 87,757 shares of the stock traded hands, compared to its average volume of 358,851. The firm has a market capitalization of $2.95 billion, a PE ratio of 35.71, a price-to-earnings-growth ratio of 1.87 and a beta of 0.78. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys, Inc. has a 1-year low of $88.81 and a 1-year high of $98.95. The business has a fifty day moving average of $95.73 and a 200-day moving average of $95.82.
Amedisys (NASDAQ:AMED - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.19 by ($0.19). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business had revenue of $587.67 million for the quarter, compared to analyst estimates of $586.75 million. During the same period in the prior year, the business earned $0.98 EPS. The company's revenue for the quarter was up 5.7% compared to the same quarter last year. Analysts expect that Amedisys, Inc. will post 4.6 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of analysts have issued reports on AMED shares. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $101.00 target price on shares of Amedisys in a report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft lowered shares of Amedisys from a "buy" rating to a "hold" rating and set a $101.00 price target on the stock. in a research report on Monday, July 29th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $100.67.
Check Out Our Latest Analysis on AMED
About Amedisys
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
See Also
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.